Maribavir mbv

Manufactured by MedChemExpress

Sourced in United States, Luxembourg

Maribavir (MBV) is a small-molecule antiviral compound developed by MedChemExpress. It is a benzimidazole riboside that inhibits the human cytomegalovirus (HCMV) UL97 protein kinase, which is essential for viral DNA replication and capsid nuclear egress.

Automatically generated - may contain errors

Lab products found in correlation

Abemaciclib, by MedChemExpress (1 mentions) Ganciclovir gcv, by Merck Group (1 mentions) Dimethyl sulfoxide (dmso), by Merck Group (1 mentions)

Spelling variants of this product

Maribavir (2 citations)

2 protocols using maribavir mbv

Antiviral Drug Acquisition and Preparation

Check if the same lab product or an alternative is used in the 5 most similar protocols

Antiviral drugs were obtained from the following sources: abemaciclib (ABE) and maribavir (MBV; MedChemExpress, Monmouth Junction, NJ, USA); TF27 (Vichem Chemie Research Ltd., Budapest, Hungary) [30 (link),61 (link),62 (link)]; letermovir (LMV; Cayman Chemical Company, Ann Arbor, MI, USA); valganciclovir (VGCV; Ratiopharm, Ulm, Germany); LDC4297 (Lead Discovery Center GmbH, Dortmund, Germany). Stock aliquots were prepared in DMSO and stored at −20 °C.

Wild M., Kicuntod J., Seyler L., Wangen C., Bertzbach L.D., Conradie A.M., Kaufer B.B., Wagner S., Michel D., Eickhoff J., Tsogoeva S.B., Bäuerle T., Hahn F, & Marschall M. (2021). Combinatorial Drug Treatments Reveal Promising Anticytomegaloviral Profiles for Clinically Relevant Pharmaceutical Kinase Inhibitors (PKIs). International Journal of Molecular Sciences, 22(2), 575.

+ Open protocol

+ Expand

Synthesis and Characterization of CDK7 Inhibitors

Cited 4 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

The synthesis and antiviral characterization of the parental, selective CDK7 inhibitor LDC4297 (Lead Discovery Center GmbH, Dortmund, Germany) have previously been described in detail [43 (link),44 (link),45 (link),47 (link),52 (link),53 (link),54 (link)]. The covalently binding derivatives QRS6, QRS7, and QRS were designed and synthesized by Qurient Co., Ltd. (C-dong, Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea; Figure S1). The antiherpesviral drugs ganciclovir (GCV; Sigma-Aldrich, St. Louis, MO, USA), cidofovir (CDV; Pharmacia & Upjohn S.A., Luxembourg, Luxembourg), and maribavir (MBV; MedChemExpress, Monmouth Junction, NJ, USA) were purchased from the indicated sources and used as reference compounds. Stock aliquots were prepared in DMSO (Sigma-Aldrich, USA) at 10 mM and stored at −20 °C.

Yu D., Wagner S., Schütz M., Jeon Y., Seo M., Kim J., Brückner N., Kicuntod J., Tillmanns J., Wangen C., Hahn F., Kaufer B.B., Neipel F., Eickhoff J., Klebl B., Nam K, & Marschall M. (2024). An Antiherpesviral Host-Directed Strategy Based on CDK7 Covalently Binding Drugs: Target-Selective, Picomolar-Dose, Cross-Virus Reactivity. Pharmaceutics, 16(2), 158.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!